What’s New with Innocoll?
Catch up on the latest developments.
Innocoll Announces Strategic Investment from Hillhouse Investment
Innocoll Announces Publication of Positive Results from Pivotal Clinical Trial of POSIMIR in Arthroscopic Subacromial Decompression
Innocoll Announces Positive Topline Results for XARACOLL® (bupivacaine hydrochloride) Implant in a Phase 3 Study to Support Expanded Use
Innocoll Announces Co-Promotion Agreement for Hernia Product Portfolio
Innocoll Announces Successful Completion of Debt Refinancing
DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)
Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant
Anthony Galdi Appointed Chief Commercial Officer of Innocoll
Louis Pascarella Appointed Chief Executive Officer of Innocoll
Innocoll Announces Commercial Launch of XARACOLL® (bupivacaine HCI) implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults